 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Domin |
| Other names | Alefexole |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H15N3S |
| Molar mass | 209.31 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
 N Y (what is this?) (verify) | |
Talipexole (B-HT920,Domnin) is adopamine agonist that is marketed as atreatment for Parkinson's Disease in Japan byBoehringer Ingelheim; it was introduced in 1996.[1] As of December 2014 it was not approved for marketing in the US nor in Europe.[2]
Talipexole is a D2dopamine receptor agonist and interacts with both pre- and post-synaptic receptors. It also is anα2-adrenergic agonist.[3]
The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.[3] In Japan,Ministry of Health, Labour and Welfare mandated in 2008 that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.[4]: 15
The N-alkylation of azepan-4-one [105416-56-6] (1) withallyl bromide in the presence of potassium carbonate gives 1-allyl-azepan-4-one (2). This is halogenated with molecular bromine in acetic acid to give 1-allyl-5-bromohexahydro-4-azepinone (3). The last step involves cyclization withthiourea (4) in refluxing ethanol, completing the synthesis of talipexole (5).
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
